Remove Access Remove Clinical Trials Remove DEA Remove Workshop
article thumbnail

What’s Next for the NIH When it Comes to Psychedelics?

Veriheal

Collins responded that they have made “some progress” but that the schedule 1 listing of the substances causes researchers to have to “overcome significant hurdles to access it”. . However, it is challenging to do this as the scheduling of substances stands in the way of accessing them- even if allocations have been made to do so. .